JafferA.AjaniMD

Clinical Trials

• SWOG-9304 Chemotherapy Plus Radiation Therapy in Treating Patients With Rectal Cancer That Has Been Surgically Removed Start of enrollment: 1994 Mar 01

  Completed

  Phase 3

• Chemotherapy Plus Radiation Therapy in Treating Patients With Stage II or Stage III Anal Cancer Start of enrollment: 1998 Oct 01

  Completed

  Phase 3

• Chemotherapy and Radiation Therapy in Treating Patients With Stomach Cancer Start of enrollment: 1999 Nov 01

  Completed

  Phase 2

• Combination Chemotherapy in Treating Patients With Unresectable Locally Advanced or Metastatic Stomach Cancer Start of enrollment: 2000 Jun 01

  Completed

  Phase 2

• Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach Start of enrollment: 2001 Apr 01

  Completed

  Phase 2

• Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer Start of enrollment: 2000 Aug 01

  Completed

  Phase 2

• Arsenic Trioxide in Treating Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction Start of enrollment: 2003 Jun 01

  Terminated

  Phase 2

• Octreotide in Preventing or Reducing Diarrhea in Patients Receiving Chemoradiotherapy for Anal or Rectal Cancer Start of enrollment: 2003 Dec 01

  Completed

  Phase 3

• Randomized Multicenter Study Comparing Docetaxel Plus Cisplatin and 5-FU to Cisplatin Plus 5-FU in Advanced Gastric Cancer Start of enrollment: 1998 Oct 01

  Completed

  Phase 2, Phase 3

• Preoperative Chemo and Chemoradiotherapy for Adenocarcinoma of the Stomach and Gastroesophageal Junction (GEJ) Start of enrollment: 2004 Jan 01

  Completed

  Phase 2

• Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma Start of enrollment: 2005 Apr 01

  Completed

  Phase 2

• Docetaxel, 5-Fluorouracil and Oxaliplatin in Adenocarcinoma of the Stomach or Gastroesophageal Junction Patients Start of enrollment: 2004 Aug 01

  Completed

  Phase 1, Phase 2

• FDG-PET-CT and Biomarkers in Esophageal Cancer Start of enrollment: 2009 Feb 01

  Completed

  Not Applicable

• Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer Start of enrollment: 2010 Mar 01

  Unknown status

  Phase 2

• Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial Start of enrollment: 2011 Apr 14

  Terminated

  Phase 3

• Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer Start of enrollment: 2012 Apr 01

  Unknown status

  Phase 2

• Study of Safety & Efficacy of the Combination of LJM716 & BYL719 in Patients With Previously Treated Esophageal Squamous Cell Carcinoma (ESCC) Start of enrollment: 2013 Jul 26

  Completed

  Phase 1

• LDE225 + Everolimus in Advanced Gastroesophageal Adenocarcinoma Start of enrollment: 2014 Nov 10

  Completed

  Phase 1

• Phase I Study of Oral DFP-11207 in Solid Tumors Start of enrollment: 2014 Jun 01

  Completed

  Phase 1

• A Phase 2 Study of Ramucirumab (LY3009806) in Participants With Gastric or Gastroesophageal Junction (GEJ) Cancer Start of enrollment: 2015 Jul 07

  Completed

  Phase 2

• Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma Start of enrollment: 2018 Feb 09

  Completed

  Early Phase 1

• Trial of DFP-14927 in Advanced Solid Tumors Start of enrollment: 2019 Sep 30

  Recruiting

  Phase 1

• Futibatinib in Patients With Specific FGFR Aberrations Start of enrollment: 2020 Aug 24

  Active, not recruiting

  Phase 2

• Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer Start of enrollment: 2020 Sep 16

  Active, not recruiting

  Phase 1

• Join now to see all